Cell stemness genes

"Cell stemness genes" refers to a set of genes whose expression maintains the stem cell phenotype, defined primarily by the abilities for self-renewal and differentiation into multiple cell types. These genes include transcription factors (such as the Sox family and POU domain proteins), cell cycle regulators, genes involved in DNA repair, apoptosis, and components of key signaling pathways (Wnt, Notch, Hedgehog, BMP, FGF), among others[1][2][3]. The precise list and importance of these genes varies by stem cell type and tissue context. In cancer biology, aberrant activation of "stemness genes" contributes to the cancer stem cell phenotype, fueling tumor growth and resistance to therapy[4]. However, because "cell stemness genes" is a broad conceptual grouping rather than a discrete entity, it cannot be directly targeted or tracked like a classical molecular target. Consequently, there are no direct drugs targeting the entity "cell stemness genes" itself; some drugs may act on individual stemness-associated gene products (e.g., Wnt inhibitors, Notch inhibitors, Hedgehog pathway modulators). The mechanisms of action are heterogeneous, pertaining to the inhibition or activation of individual gene products rather than a single unified mechanism for the conceptual group. Similarly, while individual stemness genes (such as Oct4, Sox2, Nanog, etc.) are used as biomarkers, "cell stemness genes" as a group is not considered a biomarker. The concept is important for understanding stem cell biology, regenerative medicine, and cancer, but does not uniquely specify a molecule or therapeutic target suitable for direct drug discovery or biomarker application[1][2][3][4][5].

Other names

stemness genesstem cell marker genesgenes regulating stemnesscell identity genes